Cure8 research brief
Fibrosis and strictures are important complications of IBD, especially Crohn’s disease, and there are no approved antifibrotic drugs yet. Better preclinical models guide research that could lead to treatments or preventive strategies.
Researchers studying IBD fibrosis, translational scientists developing antifibrotic therapies, and clinicians interested in the preclinical evidence base for fibrosis mechanisms and potential future treatments.
This is a review article summarizing animal and ex vivo models used to study intestinal fibrosis in IBD (especially Crohn’s disease) and how well they reproduce features of fibrostenotic disease.
The paper categorizes models (chemical, microbial/biologic, immune cell–mediated, mechanical damage/repair, genetically susceptible, cytokine-driven, radiation-induced, and organoid/ex vivo platforms) and evaluates each model’s strengths and limitations for studying extracellular matrix remodeling, fibroblast activation, chronic inflammation, tissue stiffening, muscularis propria changes, and luminal narrowing/stricture where relevant.
The review is written for researchers and clinicians aiming to select appropriate translational models to investigate fibrogenic mechanisms or to test potential antifibrotic interventions. It does not report a clinical trial or new therapy but aims to guide preclinical research model choice.
The article can help teams designing preclinical studies to match model features to the specific fibrotic process they want to study (for example, ECM remodeling vs. fixed luminal narrowing).
This item is a review (abstract-level content provided by PubMed). It summarizes existing animal and ex vivo models rather than reporting new clinical results. Findings and recommendations reflect the authors’ synthesis of preclinical literature and should not be interpreted as clinical guidance.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose. Ethical approval: Not applicable. This article is a review and does not contain any human participants or animals performed by any of the authors.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TL1A-DR3 is implicated in both inflammation and fibrosis in IBD, so targeting it could address active disease and reduce fibrotic complications that lead to strictures. New TL1A-blocking antibodies are already in...
FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
